AIM: To assess the possibility of non-invasive screening of atrophic chronic gastritis for preventing further development of gastric cancer. METHODS: One hundred and seventy-eight consecutive Helicobacter pylori (H pylori)-positive dyspeptic patients after detection of serum levels of pepsinogen-1 (PG-1) and gastrin-17 (G-17) by enzyme immunoassay were proposed for endoscopy and histology. The serologic and morphologic results were compared with estimating the sensitivity, specificity and prognostic values of the tests. RESULTS: There was statistically significant reverse dependence between the grade of stomach mucosal antral or corpus atrophy and the proper decreasing of serum G17 or PG1 levels. The serologic method was quite sensitive in the diagnosis of non-atrophic and severe antral and corpus gastritis. Also, it was characterized by the high positive and negative prognostic values. CONCLUSION: Detection of serum G-17 and PG1 levels can be offered as the screening tool for atrophic gastritis. The positive serologic results require further chromoendoscopy with mucosal biopsy, for revealing probable progressing of atrophic process with development of intestinal metaplasia, dysplasia or gastric cancer.
AIM: To assess the possibility of non-invasive screening of atrophic chronic gastritis for preventing further development of gastric cancer. METHODS: One hundred and seventy-eight consecutive Helicobacter pylori (H pylori)-positive dyspeptic patients after detection of serum levels of pepsinogen-1 (PG-1) and gastrin-17 (G-17) by enzyme immunoassay were proposed for endoscopy and histology. The serologic and morphologic results were compared with estimating the sensitivity, specificity and prognostic values of the tests. RESULTS: There was statistically significant reverse dependence between the grade of stomach mucosal antral or corpus atrophy and the proper decreasing of serum G17 or PG1 levels. The serologic method was quite sensitive in the diagnosis of non-atrophic and severe antral and corpus gastritis. Also, it was characterized by the high positive and negative prognostic values. CONCLUSION: Detection of serum G-17 and PG1 levels can be offered as the screening tool for atrophic gastritis. The positive serologic results require further chromoendoscopy with mucosal biopsy, for revealing probable progressing of atrophic process with development of intestinal metaplasia, dysplasia or gastric cancer.
Authors: P Malfertheiner; F Mégraud; C O'Morain; A P S Hungin; R Jones; A Axon; D Y Graham; G Tytgat Journal: Aliment Pharmacol Ther Date: 2002-02 Impact factor: 8.171
Authors: K Varis; P Sipponen; F Laxén; I M Samloff; J K Huttunen; P R Taylor; O P Heinonen; D Albanes; N Sande; J Virtamo; M Härkönen Journal: Scand J Gastroenterol Date: 2000-09 Impact factor: 2.423
Authors: H Väänänen; M Vauhkonen; T Helske; I Kääriäinen; M Rasmussen; H Tunturi-Hihnala; J Koskenpato; M Sotka; M Turunen; R Sandström; M Ristikankare; A Jussila; P Sipponen Journal: Eur J Gastroenterol Hepatol Date: 2003-08 Impact factor: 2.566
Authors: P Sipponen; P Ranta; T Helske; I Kääriäinen; T Mäki; A Linnala; O Suovaniemi; A Alanko; M Härkönen Journal: Scand J Gastroenterol Date: 2002-07 Impact factor: 2.423
Authors: Ali Karaman; Doğan Nasir Binici; Mehmet Eşref Kabalar; Hakan Dursun; Ali Kurt Journal: World J Gastroenterol Date: 2008-04-28 Impact factor: 5.742
Authors: Lars Agréus; Ernst J Kuipers; Limas Kupcinskas; Peter Malfertheiner; Francesco Di Mario; Marcis Leja; Varocha Mahachai; Niv Yaron; Martijn van Oijen; Guillermo Perez Perez; Massimo Rugge; Jukka Ronkainen; Mikko Salaspuro; Pentti Sipponen; Kentaro Sugano; Joseph Sung Journal: Scand J Gastroenterol Date: 2012-02 Impact factor: 2.423
Authors: Jan Bornschein; Michael Selgrad; Thomas Wex; Doerthe Kuester; Peter Malfertheiner Journal: BMC Gastroenterol Date: 2012-01-31 Impact factor: 3.067